<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744482</url>
  </required_header>
  <id_info>
    <org_study_id>I14005</org_study_id>
    <nct_id>NCT02744482</nct_id>
  </id_info>
  <brief_title>Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis</brief_title>
  <acronym>PTH</acronym>
  <official_title>Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis Double-blind Randomized Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an experimental study, prospective, comparative. This clinical trial is randomized&#xD;
      and double-blind, Residronate versus placebo.&#xD;
&#xD;
      The study aims to demonstrate the effectiveness of risedronate in pain management, after 18&#xD;
      month of traitment, in patients undergoing aseptic joint prosthesis loosening. 2 groups were&#xD;
      compared with a 1: 1 ratio. The first group receives active drug (risedronate 75mg) and the&#xD;
      second a placebo.&#xD;
&#xD;
      Patients are treated during 18 months: 1 tablet residronate/placebo per os two consecutive&#xD;
      days each month.&#xD;
&#xD;
      Evaluations are planned evry 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of patients&#xD;
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">March 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain measurement</measure>
    <time_frame>18, months</time_frame>
    <description>Measurement of pain by means of numerical rating scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain measurement at walk</measure>
    <time_frame>6 months, 12 months, 18, months, 24 moths</time_frame>
    <description>Measurement of pain by means of numerical rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain measurement at rest</measure>
    <time_frame>6 months, 12 months, 18, months, 24 moths</time_frame>
    <description>Measurement of pain by means of numerical rating scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Prosthesis Loosening</condition>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>risedrante tablet (75 mg)</description>
    <arm_group_label>Risedronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>risedrante placebo tablet (75 mg)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 18 years of age or older.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Subjects with cemented or not cemented total hip prothesis (for primitive or secondary&#xD;
             coxarthrosis)&#xD;
&#xD;
          -  Painful aseptic loosening&#xD;
&#xD;
          -  Subject has pain 4 or greater on a 10 point Visual Pain Rating scale&#xD;
&#xD;
          -  For subject woman of reproductive age, they must use reliable method(s) of&#xD;
             contraception and/or abstinence, for the duration of therapeutic product exposure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with septic loosening of hip prosthesis&#xD;
&#xD;
             . Subjects with bilateral disease&#xD;
&#xD;
          -  Subjects with implant mobility associated with pre-operative and intraoperative&#xD;
             loosening&#xD;
&#xD;
          -  Subjects under anti-osteoporotic treatment&#xD;
&#xD;
          -  Subjects having stopped a biphosphonate traetment for less than one year&#xD;
&#xD;
          -  Subjects with known allergy or sensitivity to any of the components in the study&#xD;
             medication.&#xD;
&#xD;
               -  Subjects with Hypocalcemia&#xD;
&#xD;
               -  Females who are pregnant, breast-feeding, or planning a pregnancy during the&#xD;
                  study or who think that they may be pregnant at the start of the study, or&#xD;
                  females of childbearing potential who are unable or unwilling to use a reliable&#xD;
                  form of contraception during the study.&#xD;
&#xD;
               -  Subjects with severe kidney failure ( creatinine &lt; 30 ml/min)).&#xD;
&#xD;
               -  Subjects participation in another research study&#xD;
&#xD;
               -  Subjects with previous osteonecrosis of the jaw&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prosthesis Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

